Pacific Biosciences Of California, Inc.
PACB Nasdaq· Laboratory Analytical Instruments
Last close · Oct 27, 2026
$2.45
KIRA · Stoqly’s AI analyst, in plain words
- Pacific Biosciences Of California, Inc. had $160M of revenue in fiscal 2025, up 3.9% on the year before. Over five years, revenue changed +15.2% a year on average.
- Its operating margin was −346.2%, down 38.2 pts: of every 100 in sales, about −346 is left after running the business.
- Pacific Biosciences Of California, Inc. lost $546M in fiscal 2025.
- Free cash flow was −$114M in fiscal 2025, −71.2% of revenue.
Market cap
$761M
P/E
—
Revenue
$160M
Net income
−$546M
Free cash flow
−$114M
Operating margin
−346.2%
Pacific Biosciences Of California, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+3.9%
Only a little. Sales grew 3.9% last year.
Does it make a profit?
−341.5%
No. It lost money last year.
Does profit turn into cash?
−71.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pacific Biosciences Of California, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- CIK
- 0001299130
Pacific Biosciences Of California, Inc. · PACB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $131M | $128M | $201M | $154M | $160M |
| Revenue growth | 65.4% | −1.7% | 56.3% | −23.2% | 3.9% |
| Gross margin | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating margin | −161.2% | −239.4% | −166.8% | −308.0% | −346.2% |
| Net income | −$181M | −$314M | −$307M | −$310M | −$546M |
| Net margin | −138.9% | −244.9% | −153.0% | −201.2% | −341.5% |
| Diluted EPS | −$0.89 | −$1.40 | −$1.21 | −$1.59 | −$1.82 |
| Cash | |||||
| Cash from operations | −$111M | −$263M | −$259M | −$206M | −$111M |
| Capital expenditure | $5.9M | $16.8M | $8.8M | $6.2M | $2.7M |
| Free cash flow | −$117M | −$280M | −$268M | −$212M | −$114M |
| FCF margin | −89.7% | −218.2% | −133.7% | −137.8% | −71.2% |
| Share count change | 16.7% | 10.0% | 12.9% | 13.7% | 4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $1.0B | $772M | $631M | $390M | $280M |
| Debt incl. finance leases | $898M | $899M | $0.5M | $0.0M | — |
| Shareholders' equity | $791M | $563M | $701M | $507M | $5.3M |
| Current ratio | 15.4x | 3.2x | 7.8x | 7.5x | 5.1x |
| Interest coverage | −16.8x | −20.9x | −23.3x | −35.4x | −79.6x |
| Returns and quality | |||||
| Return on capital | −25.8% | −35.2% | −375.4% | −321.2% | — |
| Return on equity | −32.2% | −46.4% | −48.5% | −51.3% | −213.5% |
| Piotroski F-score | 3 | 2 | 5 | 3 | 3 |
| Altman Z'' | 1.4 | −1.3 | −1.6 | −5.1 | −13.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.4M
4 insiders
Of sales under plans
61%
$2.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pacific Biosciences Of California, Inc. · PACB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.45 a share, the company is worth $761M.
Source: SEC EDGAR XBRL filings (CIK 0001299130). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.